paclitaxel has been researched along with Blood Pressure, High in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (10.26) | 18.2507 |
| 2000's | 9 (23.08) | 29.6817 |
| 2010's | 23 (58.97) | 24.3611 |
| 2020's | 3 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J; Marth, C; Polterauer, S; Reinthaller, A; Schauer, C; Tsibulak, I | 1 |
| Iede, K; Ikenaga, M; Matsuyama, J; Nakashima, S; Ohta, K; Tanida, T; Tominaga, S; Tsuda, Y; Ueda, M; Yamada, T | 1 |
| Ihara, Y; Imai, T; Kawai, R; Kimura, T; Otani, M; Sawa, K; Shintani, A; Takatori, S | 1 |
| Hazama, S; Inoue, Y; Kanekiyo, S; Kubo, H; Maeda, N; Matsui, H; Nagano, H; Nagashima, Y; Oka, M; Sakamoto, K; Sato, Y; Shindo, Y; Suzuki, N; Takeda, S; Ueno, T; Yamamoto, S; Yoshino, S | 1 |
| Asakura, M; Houchi, H; Kontani, K; Kosaka, S; Motoki, T; Takahashi, K; Tanaka, H; Yamaguchi, K; Yokomise, H | 1 |
| Hira, D; Ikeda, Y; Katsube, Y; Koide, H; Minegaki, T; Morita, SY; Nishiguchi, K; Terada, T; Tsujimoto, M | 1 |
| Akasaka, J; Furukawa, N; Kawaguchi, R; Kobayashi, H; Nagai, A; Sasaki, Y; Shigemitsu, A | 1 |
| Consigny, PM; Davalian, D; Donn, R; Hu, J; Rieser, M; Stolarik, D | 1 |
| Bellon, JR; Berry, DA; Carey, LA; Cirrincione, CT; Collyar, D; Golshan, M; Hahn, OM; Hudis, CA; Kuzma, CS; Perou, CM; Pluard, TJ; Port, ER; Sikov, WM; Singh, B; Somlo, G; Tolaney, SM; Winer, EP | 1 |
| Behnke-Hall, K; Esmaeili, A; Hecht, T | 1 |
| Chau, I; Smyth, EC; Tarazona, N | 1 |
| Greig, SL; Keating, GM | 1 |
| van der Woude, SO; van Laarhoven, HW | 1 |
| Awata, M; Fujita, H; Hara, H; Hozawa, H; Iijima, R; Kawai, K; Matsuyama, Y; Mukawa, H; Muramatsu, T; Nakamura, M; Nanto, S; Ochiai, M; Okada, H; Suwa, S; Yokoi, H | 1 |
| Coeffic, D; García, Y; Gebski, V; Gibbs, E; González-Martín, A; Hilpert, F; Huizing, M; Kaern, J; Kristensen, G; Lee, CK; Levaché, CB; Lück, HJ; Pujade-Lauraine, E; Roemer-Becuwe, C; Sorio, R; Witteveen, P; Zagouri, F | 1 |
| Badve, S; Cobleigh, M; Davidson, N; Dickler, M; Edgerton, S; Flockhart, DA; Gralow, J; Hancock, B; Miller, KD; Perez, EA; Radovich, M; Schneider, BP; Shenkier, T; Sledge, GW; Thor, A; Wang, M | 1 |
| Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G | 1 |
| Alì, G; Allegrini, G; Barletta, MT; Bocci, G; Bona, E; Coltelli, L; Danesi, R; Del Tacca, M; Falcone, A; Fioravanti, A; Fontanini, G; Giuntini, N; Orlandi, P | 1 |
| Chew, I; Park, KJ; Soslow, RA | 1 |
| Brahmer, JR; Dahlberg, SE; Johnson, DH; Sandler, AB; Schiller, JH | 1 |
| Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Otake, H; Sakurai, R; Shimohama, T; Tsujino, I; Waseda, K; Yamasaki, M | 1 |
| Arnold, A; Ciuleanu, T; Dediu, M; Ding, K; Ellis, PM; Fenton, D; Goodwin, R; Laberge, F; Laurie, SA; LeMaître, A; Seymour, L; Shepherd, FA; Vincent, M; Walde, D; Zukin, M | 1 |
| Amaiden, MR; Arce, CA; Campetelli, AN; Casale, CH; Monesterolo, NE; Previtali, G; Rivelli, JF; Santander, VS | 1 |
| Abaid, LN; Brown, JV; Goldstein, BH; Lopez, KL; Micha, JP; Rettenmaier, MA | 1 |
| Biganzoli, L; Bogdanova, N; Chen, Z; Cheng, Y; Chmielowska, E; Crivellari, D; Dalenc, F; Delva, R; Di Vincenzo, E; Espié, M; Hamm, C; Jiang, Z; Just, M; Lichinitser, M; Semiglazov, V; Shen, Z; Smith, I; Vinholes, J; Vivanco, GL | 1 |
| Aogi, K; Fujiwara, Y; Ito, Y; Iwata, H; Kamigaki, S; Kashiwaba, M; Masuda, N; Oda, T; Ohno, S; Takashima, S; Ueno, T | 1 |
| Itamochi, H; Sato, S | 1 |
| Amaiden, MR; Arce, CA; Campetelli, AN; Casale, CH; Hope, SI; Monesterolo, NE; Pie, J; Santander, VS; Vatta, MS | 1 |
| Coulon Sfairi, MA; Dalenc, F; Delva, R; Espié, M; Hardy-Bessard, AC; Kockler, L; Lortholary, A; Monnier, A; Pavlyuk, M; Pierga, JY; Pivot, X; Serin, D; Veyret, C | 1 |
| Sabaté, M | 1 |
| Arnold, A; Chen, E; Ellis, PM; Gauthier, I; Goss, G; Laurie, SA; Powers, J; Puchalski, TA; Robertson, J; Seymour, L; Shepherd, FA; Tu, D; Walsh, W | 1 |
| Barrett, S; Canezo, S; Seidman, AD | 1 |
| Dawson, NA; Diehl, LF; Phillips, ET; Rickles, NM; Solimando, DA; Weiss, RB | 1 |
| Hill, RJ | 1 |
| Solimando, DA | 1 |
| Genvresse, I; Harder, H; Lange, C; Possinger, K; Schanz, J; Schweigert, M; Späth-Schwalbe, E | 1 |
| Burtness, BA; Gollerkeri, A; Harrold, L; Jain, D; Rose, M | 1 |
| Arnaouti, T; Giannikos, L; Giannopoulos, A; Kalahanis, N; Karatzas, G; Kosmas, C; Polyzos, A; Sfikakis, PP; Tsavaris, N; Tsigris, C | 1 |
| Liang, ZS; Wang, LH; Yang, WX; Yu, SJ; Zhao, ZG | 1 |
3 review(s) available for paclitaxel and Blood Pressure, High
| Article | Year |
|---|---|
Ramucirumab: targeting angiogenesis in the treatment of gastric cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug Approval; Humans; Hypertension; Immunotherapy; Neovascularization, Pathologic; Neutropenia; Paclitaxel; Ramucirumab; Randomized Controlled Trials as Topic; Stomach Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Ramucirumab: A Review in Advanced Gastric Cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Esophageal Neoplasms; Humans; Hypertension; Paclitaxel; Ramucirumab; Stomach Neoplasms | 2015 |
Bevacizumab and ovarian cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Hypertension; Intestinal Perforation; Ovarian Neoplasms; Paclitaxel; Proteinuria; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
12 trial(s) available for paclitaxel and Blood Pressure, High
| Article | Year |
|---|---|
Do antihypertensive drugs really have antitumor effects? Baseline differences in hypertensive and non-hypertensive patients with advanced pancreatic cancer.
Topics: Albumins; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Hypertension; Paclitaxel; Pancreatic Neoplasms; Prospective Studies; Retrospective Studies | 2022 |
A phase II, multicenter, single-arm study of tri-weekly low-dose nanoparticle albumin-bound paclitaxel chemotherapy for patients with metastatic or recurrent breast cancer.
Topics: Aged; Albumins; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Incidence; Leukopenia; Middle Aged; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Treatment Outcome | 2017 |
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Drug Administration Schedule; Fatigue; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neutropenia; Paclitaxel; Remission Induction; Thrombocytopenia; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Disease-Free Survival; Doxorubicin; Drug Resistance, Neoplasm; Female; Humans; Hypertension; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Patient Selection; Platinum Compounds; Polyethylene Glycols; Topotecan | 2017 |
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Genotype; Haplotypes; Humans; Hypertension; Paclitaxel; Polymorphism, Single Nucleotide; Proportional Hazards Models; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blood Pressure; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Hypertension; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Survival Rate; Treatment Outcome | 2010 |
Vascular response to overlapping everolimus-eluting stents. - Comparison with paclitaxel-eluting stents -.
Topics: Aged; Antineoplastic Agents, Phytogenic; Diabetes Mellitus; Drug-Eluting Stents; Everolimus; Female; Follow-Up Studies; Humans; Hyperlipidemias; Hypertension; Immunosuppressive Agents; Male; Middle Aged; Paclitaxel; Retrospective Studies; Sirolimus; Ultrasonography, Interventional | 2010 |
Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Placebos; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Hypertension; Paclitaxel; Taxoids; Vinblastine; Vinorelbine | 2012 |
First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Hypertension; Japan; Middle Aged; Paclitaxel; Receptor, ErbB-2 | 2011 |
[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Docetaxel; Female; Hemorrhage; Humans; Hypertension; Middle Aged; Neutropenia; Paclitaxel; Proteinuria; Taxoids; Thromboembolism; Young Adult | 2012 |
Phase I and pharmacokinetic study of daily oral AZD2171, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with carboplatin and paclitaxel in patients with advanced non-small-cell lung cancer: the National Cancer Institut
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Hematologic Diseases; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
24 other study(ies) available for paclitaxel and Blood Pressure, High
| Article | Year |
|---|---|
Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Austria; Bevacizumab; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Hypertension; Ovarian Neoplasms; Paclitaxel; Proteinuria | 2022 |
Renin-angiotensin-aldosterone system inhibitors are associated with improved paclitaxel-induced peripheral neuropathy in lung cancer: a study using administrative claims data.
Topics: Antihypertensive Agents; Cohort Studies; Humans; Hypertension; Lung Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Quality of Life; Renin-Angiotensin System | 2023 |
Hypertension and Proteinuria as Predictive Factors of Effects of Bevacizumab on Advanced Breast Cancer in Japan.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Bevacizumab; Breast Neoplasms; Female; Humans; Hypertension; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Proteinuria; Treatment Outcome | 2018 |
Concomitant administration of candesartan cilexetil in patients on paclitaxel and carboplatin combination therapy increases risk of severe neutropenia
.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Carboplatin; Drug Interactions; Female; Humans; Hypertension; Incidence; Japan; Male; Middle Aged; Neutropenia; Paclitaxel; Retrospective Studies; Risk Factors; Severity of Illness Index; Tetrazoles; Time Factors; Treatment Outcome | 2018 |
Evaluation of the relation between patient characteristics and the state of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Carboplatin; Dexamethasone; Female; Genital Neoplasms, Female; Granisetron; Humans; Hyperemesis Gravidarum; Hypertension; Middle Aged; Multivariate Analysis; Nausea; Paclitaxel; Pregnancy; Retrospective Studies; Surveys and Questionnaires; Vomiting | 2014 |
Chemical renal denervation in the rat.
Topics: Animals; Chromatography, Liquid; Denervation; Disease Models, Animal; Dose-Response Relationship, Drug; Guanethidine; Hypertension; Kidney; Mass Spectrometry; Norepinephrine; Paclitaxel; Phenol; Rats; Rats, Sprague-Dawley; Salicylic Acid; Saline Solution, Hypertonic | 2014 |
Balloon angioplasty of the bilateral renal arteries by Takayasu arteritis with a paclitaxel-eluting balloon.
Topics: Angioplasty, Balloon; Child; Female; Humans; Hypertension; Magnetic Resonance Angiography; Paclitaxel; Renal Artery; Stents; Takayasu Arteritis; Treatment Outcome | 2015 |
Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer.
Topics: Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Humans; Hypertension; Infusions, Intravenous; Male; Paclitaxel; Ramucirumab; Stomach Neoplasms; Vascular Endothelial Growth Factor A | 2016 |
Effect of Optimal Medical Therapy Before Procedures on Outcomes in Coronary Patients Treated With Drug-Eluting Stents.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Blood Pressure; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Diabetes Mellitus; Drug-Eluting Stents; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Japan; Male; Middle Aged; Paclitaxel; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Sirolimus | 2016 |
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles | 2009 |
Discordant somatic and germline VEGF-A genotype in a cancer patient resistant to paclitaxel/bevacizumab with chemosensitive hepatic metastasis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma, Ductal, Breast; Disease-Free Survival; DNA; DNA, Neoplasm; Drug Resistance, Neoplasm; Female; Genotype; Humans; Hypertension; Liver Neoplasms; Middle Aged; Neovascularization, Pathologic; Paclitaxel; Polymorphism, Genetic; Vascular Endothelial Growth Factor A | 2009 |
Morphologic changes in ovarian carcinoma after neoadjuvant chemotherapy: report of a case showing extensive clear cell changes mimicking clear cell carcinoma.
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Cystadenocarcinoma, Serous; Diagnosis, Differential; Female; Humans; Hypercholesterolemia; Hypertension; Immunohistochemistry; Neoadjuvant Therapy; Ovarian Neoplasms; Paclitaxel; Pleural Effusion, Malignant | 2009 |
Tubulin pools in human erythrocytes: altered distribution in hypertensive patients affects Na+, K+-ATPase activity.
Topics: Acetylation; Adult; Aged; Antibodies, Monoclonal; Cell Membrane; Erythrocytes; Female; Humans; Hypertension; Male; Middle Aged; Nocodazole; Paclitaxel; Sodium-Potassium-Exchanging ATPase; Tubulin | 2011 |
Bevacizumab, paclitaxel and carboplatin for advanced ovarian cancer: low risk of gastrointestinal and cardiovascular toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Female; Humans; Hypertension; Incidence; Intestinal Perforation; Middle Aged; Ovarian Neoplasms; Paclitaxel; Retrospective Studies; Risk | 2010 |
Involvement of membrane tubulin in erythrocyte deformability and blood pressure.
Topics: Adult; Animals; Blood Pressure; Cell Membrane; Erythrocyte Deformability; Humans; Hypertension; Male; Membrane Proteins; Microscopy, Fluorescence; Nocodazole; Paclitaxel; Rats; Rats, Inbred SHR; Rats, Wistar; Tubulin | 2012 |
[Insulin-dependent. Rapamycin-resistant?].
Topics: Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Restenosis; Cost-Benefit Analysis; Data Interpretation, Statistical; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Drug Delivery Systems; Female; Humans; Hypertension; Immunosuppressive Agents; Incidence; Male; Meta-Analysis as Topic; Myocardial Infarction; Paclitaxel; Randomized Controlled Trials as Topic; Registries; Risk Factors; Sirolimus; Stents; Treatment Outcome | 2006 |
Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2.
Topics: Breast Neoplasms; Female; Humans; Hypertension; Paclitaxel; Vision Disorders | 1994 |
Hypertensive reactions associated with paclitaxel.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Blood Pressure; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Female; Fluorouracil; Humans; Hypertension; Methotrexate; Middle Aged; Ovarian Neoplasms; Paclitaxel | 1996 |
Manufacturer's labeling for paclitaxel.
Topics: Antineoplastic Agents, Phytogenic; Drug Labeling; Humans; Hypertension; Paclitaxel | 1996 |
Paclitaxel package insert.
Topics: Antineoplastic Agents, Phytogenic; Drug Labeling; Humans; Hypertension; Paclitaxel | 1997 |
Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Amifostine; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Hypocalcemia; Hypotension; Infusions, Intravenous; Lung Neoplasms; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Paclitaxel; Pancreatic Neoplasms; Platinum; Prednisone; Premedication; Retrospective Studies; Vincristine | 2001 |
Use of paclitaxel in patients with pre-existing cardiomyopathy: a review of our experience.
Topics: Aged; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cardiomyopathies; Doxorubicin; Female; Humans; Hypertension; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Retrospective Studies; Ventricular Function, Left | 2001 |
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Spasm; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Drug Hypersensitivity; Edema; Erythema; Female; Greece; Humans; Hypertension; Hypotension; Injections, Intraperitoneal; Injections, Intravenous; Ovarian Neoplasms; Paclitaxel; Pruritus; Retrospective Studies; Tachycardia | 2001 |
Control of hypertension in rats using volatile components of leaves of Taxus chinensis var. mairei.
Topics: Administration, Oral; Angiotensin II; Animals; Antihypertensive Agents; Biomarkers; Blood Glucose; Blood Pressure; Chromatography, Supercritical Fluid; Disease Models, Animal; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Hydrochlorothiazide; Hypertension; Lipids; Male; Nitric Oxide; Nitroarginine; Phytotherapy; Plant Leaves; Plants, Medicinal; Rats; Rats, Sprague-Dawley; Taxus; Time Factors; Volatilization | 2012 |